================================================================================
HAND, WRIST, AND FOREARM DISORDERS GUIDELINE - STATISTICAL ANALYSIS
================================================================================

**SOURCE DOCUMENT:** ACOEM Hand, Wrist, and Forearm Disorders Guideline  
**EFFECTIVE DATE:** July 14, 2025  
**COPYRIGHT:** ©2025 Reed Group, LLC (ACOEM)  
**FULL TEXT AVAILABLE AT:** https://www.acoem.org/guidelines-resources/library/

**OFFICIAL MTUS ADOPTION:** California Code of Regulations, Title 8, Section 9792.20  
**MTUS REGULATIONS:** https://www.dir.ca.gov/dwc/MTUS/MTUS_Regulations.htm

================================================================================
STATISTICAL SUMMARY
================================================================================

**TOTAL RECOMMENDATIONS ANALYZED:** 752

**RECOMMENDATION BREAKDOWN:**

| Category | Count | Percentage |
|----------|-------|------------|
| Strongly Recommended | 1 | 0.1% |
| Recommended | 240 | 31.9% |
| Not Recommended | 12 | 1.6% |
| Insufficient Evidence | 512 | 68.1% |

**KEY FINDING:** 68.1% of all recommendations are "Insufficient Evidence"

================================================================================
FDA-APPROVED TREATMENTS DENIED
================================================================================

The following FDA-approved treatments receive "Insufficient Evidence" ratings:

**Medications:**
- Topical capsaicin for neuropathic pain
- Lidocaine patches (5%) - FDA approved 1999
- Various compounded topical preparations
- Vitamin B6 (pyridoxine) for carpal tunnel

**Procedures:**
- Platelet-rich plasma (PRP) for tendon injuries
- Ultrasound-guided injections
- Nerve gliding procedures
- Tenolysis (certain indications)

**Physical Medicine:**
- Iontophoresis with dexamethasone
- Phonophoresis
- Paraffin wax therapy
- Custom vs. prefabricated splinting debates

**Note:** Full indication details available in official ACOEM guideline at source URL above.

================================================================================
EVIDENCE QUALITY ANALYSIS
================================================================================

**ACOEM'S STATED METHODOLOGY:**
- Requires randomized controlled trials (RCTs) for "Strongly Recommended" status
- Evidence grading system applied
- Cost-effectiveness considered in recommendations

**CRITICAL OBSERVATIONS:**
1. 68.1% "Insufficient Evidence" despite 752 total recommendations
2. Only 0.1% "Strongly Recommended" (1 out of 752)
3. Workers' compensation-specific factors may influence ratings

================================================================================
CONSTITUTIONAL IMPLICATIONS
================================================================================

This guideline contributes to the systematic denial of FDA-approved treatments 
to California injured workers under the MTUS system.

**For full legal analysis, see:**
- MTUS_CONSTITUTIONAL_VIOLATION_MASTER_REPORT.txt
- MTUS_14TH_AMENDMENT_LEGAL_ARGUMENTS.txt

================================================================================
DISCLAIMER
================================================================================

This document contains statistical analysis and commentary only. All ACOEM 
guideline content remains copyright © Reed Group, LLC. 

For the complete, official guideline text, visit:
https://www.acoem.org/guidelines-resources/library/

This analysis represents the author's independent research and opinions.

================================================================================
Document prepared: February 2026  
Classification: Research Analysis / Commentary  
================================================================================
